3-[(5Z)-5-(4-hydroxybenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-[(5Z)-5-(4-hydroxybenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
• 英文别名: 3-[(5Z)-5-[(4-hydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid
• 化学式: C₁₃H₁₁NO₄S₂
• 分子量: 309.4
• InChiKey: JRFVMRNBAOSUAF-YFHOEESVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  135
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] INHIBITION OF CLATHRIN<br/>[FR] INHIBITION DE LA CLATHRINE
  申请人：UNIV BERLIN FREIE

  公开号：WO2013010218A9

  公开（公告）日：2013-03-28
• Oxazole and thiazole compounds as beta-catenin modulators and uses thereof
  申请人：Dasgupta Ramanuj

  公开号：US20090227624A1

  公开（公告）日：2009-09-10

  A series of oxazole and thiazole compounds are shown herein to be small molecule inhibitors of the Wnt pathway that specifically target the activity of the stabilized pool of β-cat oxazole and thiazole compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cancer, and others.
• OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF
  申请人：DASGUPTA Ramanuj

  公开号：US20120264744A1

  公开（公告）日：2012-10-18

  A series of oxazole and thiazole compounds are shown herein to be small molecule inhibitors of the Wnt pathway that specifically target the activity of the stabilized pool of β-catenin. Oxazole and thiazole compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cancer, and others.
• MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE
  申请人：Zender Lars

  公开号：US20140141510A1

  公开（公告）日：2014-05-22

  The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
• US8252823B2
  申请人：——

  公开号：US8252823B2

  公开（公告）日：2012-08-28